The challenges of adherence and persistence with iron chelation therapy

被引:40
作者
Porter, John B. [2 ]
Evangeli, Michael [3 ]
El-Beshlawy, Amal [1 ]
机构
[1] Cairo Univ, Cairo, Egypt
[2] UCL, UCL Canc Inst, Dept Haematol, London WC1E 6BT, England
[3] Univ London, London, England
关键词
Adherence; Persistence; Iron chelation therapy; BETA-THALASSEMIA MAJOR; PATIENT-REPORTED OUTCOMES; LABILE PLASMA IRON; MYELODYSPLASTIC SYNDROMES; MEDICATION COMPLIANCE; OVERLOADED PATIENTS; DEFEROXAMINE; DEFERIPRONE; DEFERASIROX; TRANSFUSION;
D O I
10.1007/s12185-011-0927-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Due to advances in medical sciences, many chronic diseases that formerly resulted in early death can now be effectively managed with long-term treatment regimens. Patients with potentially fatal anemias, for example, can be treated with ongoing blood transfusions and iron chelation therapy. Ensuring adherence and persistence is challenging, as the benefits of therapy are not perceived immediately. Poor adherence severely compromises the effectiveness of treatment and, therefore, improving compliance in terms of quality of life and health economics is critical. Although adherence to chelation therapy is generally poor, the availability of oral iron chelators may help to improve patient compliance. For chronic conditions such as thalassemia major, even when oral chelation therapy is available, support by an integrated team including a clinical psychologist and nurse specialist working with the treatment center is recommended to achieve optimal results.
引用
收藏
页码:453 / 460
页数:8
相关论文
共 40 条
[1]   PHARMACOKINETICS OF THE ORAL IRON CHELATOR DEFERIPRONE (L(1)) IN PATIENTS WITH IRON OVERLOAD [J].
ALREFAIE, FN ;
SHEPPARD, LN ;
NORTEY, P ;
WONKE, B ;
HOFFBRAND, AV .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (02) :403-408
[2]   An empirical test of the Information, Motivation and Behavioral Skills model of antiretroviral therapy adherence [J].
Amico, KR ;
Toro-Alfonso, J ;
Fisher, JD .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2005, 17 (06) :661-673
[3]  
[Anonymous], 2005, ADHERENCE LONG TERM
[4]  
[Anonymous], 2007, FERR PRESCR INF
[5]  
Borgna-Pignatti C, 2004, HAEMATOLOGICA, V89, P1187
[6]   EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR [J].
BRITTENHAM, GM ;
GRIFFITH, PM ;
NIENHUIS, AW ;
MCLAREN, CE ;
YOUNG, NS ;
TUCKER, EE ;
ALLEN, CJ ;
FARRELL, DE ;
HARRIS, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (09) :567-573
[7]   LPI-labile plasma iron in iron overload [J].
Cabantchik, ZI ;
Breuer, W ;
Zanninelli, G ;
Cianciulli, R .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (02) :277-287
[8]   Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia [J].
Cappellini, Maria Domenica ;
Bejaoui, Mohamed ;
Agaoglu, Leyla ;
Porter, John ;
Coates, Thomas ;
Jeng, Michael ;
Lai, Maria Eliana ;
Mangiagli, Antonio ;
Strauss, Gabriele ;
Girot, Robert ;
Watman, Nora ;
Ferster, Alina ;
Loggetto, Sandra ;
Abish, Sharon ;
Cario, Holger ;
Zoumbos, Nicolaos ;
Vichinsky, Elliott ;
Opitz, Herbert ;
Ressayre-Djaffer, Catherine ;
Abetz, Linda ;
Rofail, Diana ;
Baladi, Jean-Francois .
CLINICAL THERAPEUTICS, 2007, 29 (05) :909-917
[9]   Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias [J].
Cappellini, Maria Domenica ;
Porter, John ;
El-Beshlawy, Amal ;
Li, Chi-Kong ;
Seymour, John F. ;
Elalfy, Mohsen ;
Gattermann, Norbert ;
Giraudier, Stephane ;
Lee, Jong-Wook ;
Chan, Lee Lee ;
Lin, Kai-Hsin ;
Rose, Christian ;
Taher, Ali ;
Thein, Swee Lay ;
Viprakasit, Vip ;
Habr, Dany ;
Domokos, Gabor ;
Roubert, Bernard ;
Kattamis, Antonis .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (04) :557-566
[10]   Overcoming the challenge of patient compliance with iron chelation therapy [J].
Cappellini, MD .
SEMINARS IN HEMATOLOGY, 2005, 42 (02) :S19-S21